NV-102

N/A

Report date: 2024/02/05 14:01:22

Base Information

Drug NameNV-102

Drug Alias NameNV-102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Doxorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CD19Topoisomerase II inhibitors

TargetsB-lymphocyte antigen CD19Topoisomerase II

Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNanovalent Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesNanovalent Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A